Adebrelimab Plus Apatinib for Maintenance Treatment of Extensive Stage Small Cell Lung Cancer After First-line Induction with Adebrelimab Plus Chemotherapy (CLOG2402-ADAPT): a Multi-center, Single-arm, Phase 2 Clinical Trial
Latest Information Update: 09 Jan 2025
At a glance
- Drugs Adebrelimab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms CLOG2402-ADAPT
Most Recent Events
- 20 Dec 2024 Status changed from not yet recruiting to recruiting.
- 03 Jul 2024 New trial record